CD30 est universellement exprimé sur les cellules de Reed-Sternberg dans le lymphome classique Hodgkin et i...
Vue déterministe de l'entité source de la LJAM. L'autorité clinique demeure avec les ID de la source cités et l'état d'approbation de l ́examinateur.
| ID | BMA-CD30-CHL |
|---|---|
| Type | Pertinence thérapeutique |
| État | reviewed 2026-04-27 | pending_clinical_signoff | actionability review required |
| Maladies | DIS-CHL |
| Sources | SRC-ESMO-HODGKIN-2024 SRC-NCCN-BCELL-2025 |
Faits relatifs à l ' action en justice
| Biomarqueur | BIO-CD30-IHC |
|---|---|
| Variante | expression CD30 sur les cellules Reed-Sternberg / Hodgkin (~100% positif par IHC — caractéristique déterminante du lymphome classique Hodgkin) |
| Maladie | DIS-CHL |
| Niveau ESCAT | IA |
| Combinaisons recommandées | A+AVD (brentuximab vedotin + AVD) — 1L stage III/IV cHL per SRC-NCCN-BCELL-2025, SRC-ESMO-HODGKIN-2024, brentuximab vedotin + nivolumab — R/R cHL pre-/post-autoHCT per SRC-NCCN-BCELL-2025, brentuximab vedotin consolidation post-autoHCT — high-risk R/R cHL per SRC-NCCN-BCELL-2025 |
| Contre-indiqué en monothérapie | brentuximab vedotin + bleomycin (pulmonary toxicity contraindication per ECHELON-1) |
| Résumé des faits | CD30 is universally expressed on Reed-Sternberg cells in classical Hodgkin lymphoma and is the target of brentuximab vedotin (BV), an anti-CD30 antibody-drug conjugate (auristatin payload). 1L advanced- stage cHL: A+AVD (BV + doxorubicin/vinblastine/dacarbazine) is preferred over ABVD per ECHELON-1 (Ansell NEJM 2022 — 6y OS 93.9% vs 89.4%, HR 0.59) per SRC-NCCN-BCELL-2025, SRC-ESMO-HODGKIN-2024. Pediatric AHOD1331 supported BV + AVE-PC for high-risk pediatric. R/R cHL: BV monotherapy and BV + nivolumab are standard pre-/post- HCT options. BV consolidation post-autoHCT for high-risk R/R cHL (AETHERA Younes Lancet 2015 — improves PFS) per SRC-NCCN-BCELL-2025. |
Notes
ESCAT IA / OncoKB Level 1. CD30 IHC is universally positive in cHL, so the biomarker is essentially a histologic-confirmation gate rather than a selection threshold for the drug class. Bibliographic records SRC-ECHELON-1-CONNORS-2018 and SRC-AETHERA-MOSKOWITZ-2015 are available; SRC-CHECKMATE-744 remains a source gap and claim-level linkage requires clinical sign-off. PD-1 checkpoint inhibitors (pembrolizumab KEYNOTE-204, nivolumab CheckMate-205) are alternative biology-driven options in R/R cHL.
Utilisé par
No reverse references found in the YAML corpus.